Compassionate Use
Compliant Early Access
Providing access to investigational or locally unapproved medicines when no other options exist.
Our Access Programs
Named Patient Sales
Commercial Distribution
Tender Supply
Post Trial Supply
Market Shortages
Market Withdrawals
Protocol-Based Access
Emergency Supply
Supply to Investigator Studies
Donation Programs
treatment when options run out.
Compassionate Use (also known as Named Patient Programs, Expanded Access, or Special Access Schemes) enables manufacturers to provide a locally unapproved drug free-of-charge, on a controlled patient-by-patient basis for serious or life-threatening conditions. These programs help eligible patients receive vital therapies while supporting ethical obligations and strengthening clinical engagement in markets where commercial availability may be delayed—or may never occur.
scenarios for Compassionate Use:
-
Patients have no satisfactory licensed therapy available.
-
The medicine isn’t approved locally but can be provided free-of-charge case-by-case.
-
Market rollout is slow or staggered, creating temporary treatment gaps.
-
Clinicians need rapid access for individual patients or defined cohorts.
-
Different countries receive approval at different times, limiting availability.
-
Rare diseases, oncology, and genetic disorders require fast intervention.
our approach to Compassionate Use
-
![Line drawing of a test tube with DNA strands, capsules, a molecular structure, and a pill, representing biotechnology or pharmaceutical research.]()
Pharmacovigilance
In compliance with country-specific PV regulations, we manage spontaneous safety reporting and compliant event capture throughout the CU program lifecycle. Learn more.
-
![Line drawing of a checklist with five checked boxes and a ribbon with a checkmark, all enclosed in a circle.]()
Regulatory
Compassionate Use requirements vary by country. Tanner designs CU programs, manages submissions, guides manufacturers through controlled, patient-specific access pathways, and supports scenarios where a product may never receive full commercial authorization. Learn more.
-
![A line drawing of a hand holding a badge with a checkmark symbol, representing quality or certification.]()
Medical Affairs
Our team offers scientific and clinical expertise supporting eligibility assessments, HCP engagement, medical inquiry response, and appropriate use of investigational or unapproved products. Learn more.
-
![Icon of a cardboard box with recycling arrows around it.]()
Supply Chain & Logistics
GDP-compliant warehousing, cold chain capabilities, controlled substances handling, and specialty logistics ensure secure delivery of unapproved medicines to sites in high-acuity or resource-restricted environments. Learn more.
-
![Outline of web development or coding web page with code snippets on a computer screen icon.]()
Program Management
A dedicated Program Manager oversees all day-to-day operations, timelines, stakeholder communications, and risk mitigation while our US and EU-based Customer Advocates serve as the primary POC for Tanner customers, pharmacists and physicians.
-
![Illustration of four people connected by arrows, with speech bubbles in the center, representing communication or teamwork.]()
Program Awareness
We provide guidance on compliant, strategic program awareness to help clinicians, treatment centers and patients effectively discover CU options.
add-on Compassionate Use Services
-
Strategic and tactical guidance at evaluation stage on all program types at product or portfolio level.
-
Strategic and tactical guidance at evaluation stage on all program types at product or portfolio level.
-
Strategic and tactical guidance at evaluation stage on all program types at product or portfolio level.